Big results in prostate cancer

Posted 1 December 2023 AM

Sydney-based Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company, has achieved spectacular results in its Phase 1/2a SECuRe study, with the first patient to receive two doses seeing their cancer drop to undetectable levels.

Patients with metastatic castrate-resistant prostate cancer have been receiving single escalating doses of four, eight, or twelve GBq of Cu-SAR-bisPSMA, but after a request from a clinician one patient received a second dose under the FDA's expanded access program.

To see the whole article, please login